Search results for "CD1"

showing 10 items of 333 documents

Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia.

2010

Abstract Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic disorder that occurs in elderly patients. One of the main diagnostic criteria is the accumulation of heterogeneous monocytes in the peripheral blood. We further explored this cellular heterogeneity and observed that part of the leukemic clone in the peripheral blood was made of immature dysplastic granulocytes with a CD14−/CD24+ phenotype. The proteome profile of these cells is dramatically distinct from that of CD14+/CD24− monocytes from CMML patients or healthy donors. More specifically, CD14−/CD24+ CMML cells synthesize and secrete large amounts of alpha-defensin 1-3 (HNP1-3). Recombinant HNPs inhibit macrophage co…

Macrophage colony-stimulating factoralpha-DefensinsCD14Cellular differentiationImmunologyLipopolysaccharide ReceptorsChronic myelomonocytic leukemiaUridine TriphosphateBiologyGranulocyteBiochemistryMonocytesUridine DiphosphatemedicineMacrophageHumansReceptors Purinergic P2MonocyteMacrophage Colony-Stimulating FactorMacrophagesCD24 AntigenCell DifferentiationLeukemia Myelomonocytic ChronicCell BiologyHematologymedicine.diseaseHaematopoiesismedicine.anatomical_structureCancer researchCytokinesGranulocytesBlood
researchProduct

Phenotypic characterisation of pro-inflammatory monocytes and dendritic cells in peripheral arterial disease

2012

SummaryAtherosclerosis is a chronic inflammatory process involving antigen-presenting cells like monocytes and dendritic cells (DC). The aim of this study was to perform a phenotypic characterisation of these cell types in patients with different degrees of peripheral arterial disease (PAD). Sixty patients with PAD [N= 30 intermittent claudication (IC), N= 30 critical limb ischemia (CLI)] and 30 controls were included. Peripheral blood leucocytes were analysed from peripheral blood by flow cytometry using different gating strategies to directly identify and analyse monocytes, myeloid DC, (mDC) and plasmacytoid DC (pDC). PAD patients showed a significantly higher proportion of proinflammator…

Male0301 basic medicineCD14Inflammation030204 cardiovascular system & hematologyCD16Peripheral blood mononuclear cellMonocytesImmunophenotypingProinflammatory cytokinePeripheral Arterial Disease03 medical and health sciences0302 clinical medicineIschemiamedicineHumansCD40 AntigensAgedAged 80 and overCD40biologybusiness.industryExtremitiesDendritic CellsHLA-DR AntigensHematologyCritical limb ischemiaIntermittent ClaudicationMiddle AgedIntermittent claudicationBlood Cell Countbody regions030104 developmental biologyCase-Control StudiesImmunologybiology.proteinFemaleB7-2 AntigenInflammation Mediatorsmedicine.symptombusinessThrombosis and Haemostasis
researchProduct

Circulating monocyte subsets and heart failure prognosis

2018

Altres ajuts: Fundacio' La MARATO' de TV3 (201502 to ABG, 201516), AdvanceCat with the support of ACCIÓ [Catalonia Trade & Investment, Generalitat de Catalunya], Fundació Bancària La Caixa. Monocytes are a heterogeneous population of effector cells with key roles in tissue integrity restoration and maintenance. Here, we explore the association of monocyte subsets and prognosis in patients with ambulatory heart failure (HF). Monocyte subsets were classified as classical (CD14 ++ /CD16 -), intermediate (CD14 ++ /CD16 +), or non-classical (CD14 + /CD16 ++). Percentage distribution and absolute cell count were assessed in each subset, and multivariable Cox regression analyses were performed wit…

Male0301 basic medicineEtiologylcsh:Medicine030204 cardiovascular system & hematologyPathology and Laboratory MedicineMonocytesWhite Blood CellsMathematical and Statistical Techniques0302 clinical medicineAnimal CellsCell MovementRisk FactorsCause of DeathMedicine and Health Scienceslcsh:ScienceCause of deathMultidisciplinaryEjection fractionHeartPrognosismedicine.anatomical_structurePhysical SciencesAmbulatoryCardiologyRegression AnalysisFemaleCellular TypesAnatomyStatistics (Mathematics)Research Articlemedicine.medical_specialtyImmune CellsCD14ImmunologyCell Enumeration TechniquesCardiologyResearch and Analysis MethodsDisease-Free Survival03 medical and health sciencesDiagnostic MedicineInternal medicinemedicineHumansStatistical MethodsAgedProportional Hazards ModelsHeart FailureBlood Cellsbusiness.industryProportional hazards modelMonocytelcsh:RBiology and Life SciencesCell Biologymedicine.disease030104 developmental biologyVentricleHeart failureCardiovascular Anatomylcsh:QbusinessMathematicsEjection FractionPLOS ONE
researchProduct

PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: A expression patterns and clinical implications

2018

Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), a variant of pancreatic ductal adenocarcinoma (PDAC), has a striking genetic similarity to PDAC but a significantly improved overall survival. We hypothesize that this difference could be due to the immune response to the tumor, and as such, we investigated the expression of PD-1, PD-L1, and CD163 in a series of UCOGC. To this aim, 27 pancreatic UCOGCs (11 pure and 16 PDAC-associated), 5 extrapancreatic tumors with osteoclast-like giant cells and 10 pancreatic anaplastic carcinomas were immunostained using antibodies against PD-1, PD-L1, and CD163. In pancreatic UCOGCs, PD-L1 was expressed in neoplastic cells of 17 (63%) o…

Male0301 basic medicineIndianaProgrammed Cell Death 1 ReceptorOsteoclast; PDAC; Pancreatic Cancer; Tumor-Associated Macrophages; UCOGCOsteoclastsGiant CellsB7-H1 Antigen0302 clinical medicineTumor-Associated MacrophagesTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]LymphocytesAged 80 and overbiologyTumor-associated macrophagesCell DifferentiationMiddle AgedOsteoclast; Pancreatic cancer; PDAC; Tumor-associated macrophages; UCOGC; 2734ImmunohistochemistryEuropePhenotypemedicine.anatomical_structure030220 oncology & carcinogenesisOsteoclastFemaleAntibodyCarcinoma Pancreatic DuctalAdult2734Antigens Differentiation MyelomonocyticReceptors Cell SurfaceUCOGCPathology and Forensic MedicinePancreatic Cancer03 medical and health sciencesImmune systemAll institutes and research themes of the Radboud University Medical CenterAntigens CDOsteoclastPD-L1Pancreatic cancerBiomarkers TumormedicineHumansHistiocyteAgedNeoplasm StagingPDACHistiocytesPancreatic cancermedicine.diseasePancreatic Neoplasms030104 developmental biologyGiant cellCancer researchbiology.proteinCD163
researchProduct

Polymorphonuclear leukocyte integrins in deep venous thrombosis

2005

The polymorphonuclear leukocytes (PMN) have a role in the pathophysiology of deep venous thrombosis (DVT). We examined the phenotypical expression of PMN beta2-integrins (CD l l a, CDl l b, CD 11c) in a group of 19 subjects with leg DVT. PMN cells were incubated with fluorescent monoclonal antibodies against CD11a, CD11b, CD11c, and the evaluation was made by flow cytofluorimetry. The same integrins were determined after in vitro activation with 4-phorbol 12-myristate 13-acetate (PMA) and N-formylmethionyl-leucyl-phenylalanine (fMLP). In DVT subjects, at baseline, the phenotypical expression of CD11b was decreased and that of CD11c increased when compared with normal controls. In normal su…

Male0301 basic medicineIntegrinsNeutrophilsmedicine.drug_classIntegrinCD11a030204 cardiovascular system & hematologyMonoclonal antibody03 medical and health scienceschemistry.chemical_compound0302 clinical medicinepolymorphonuclear leukocyte integrinmedicineHumansdeep venous thrombosiVenous ThrombosisbiologyCell adhesion moleculebusiness.industryhemic and immune systemsHematologyGeneral MedicineMiddle AgedN-Formylmethionine leucyl-phenylalaninemedicine.diseasePathophysiologyN-Formylmethionine Leucyl-PhenylalanineVenous thrombosis030104 developmental biologychemistryIntegrin alpha MImmunologybiology.proteinTetradecanoylphorbol AcetateFemalebusinesspolymorphonuclear leukocyte activation
researchProduct

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma : Final …

2016

Purpose Blinatumomab is a CD19/CD3 BiTE (bispecific T-cell engager) antibody construct for the treatment of Philadelphia chromosome–negative acute B-lymphoblastic leukemia. We evaluated blinatumomab in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Patients and Methods This 3 + 3 design, phase I dose-escalation study determined adverse events and the maximum tolerated dose (MTD) of continuous intravenous infusion blinatumomab in patients with relapsed/refractory NHL. Blinatumomab was administered over 4 or 8 weeks at seven different dose levels (0.5 to 90 μg/m2/day). End points were incidence of adverse events, pharmacokinetics, pharmacodynamics, and overall response rate. Results B…

Male0301 basic medicineOncologyCancer ResearchCD3 ComplexT-Lymphocytesmedicine.medical_treatmentMedizinLymphoma Mantle-CellLymphocyte Activation0302 clinical medicineRecurrenceGermanyhemic and lymphatic diseasesAntibodies BispecificMedicineMolecular Targeted TherapyInfusions IntravenousLymphoma FollicularLymphoma Non-HodgkinRemission InductionMiddle AgedLeukemiaTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleBlinatumomabImmunotherapymedicine.drugAdultmedicine.medical_specialtyLymphoma B-CellMaximum Tolerated DoseAntigens CD19Antineoplastic AgentsDrug Administration Schedule03 medical and health sciencesPharmacokineticsRefractoryInternal medicineHumansAdverse effectbusiness.industryImmunotherapymedicine.diseaseLymphomaSurgery030104 developmental biologyPharmacodynamicsNervous System Diseasesbusiness
researchProduct

Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases

2017

Background The expression of CD70 on T cells is greatly enhanced by antigen-presenting cell (APC)-associated signals, such as tumour necrosis factor(TNF)-α, which is constitutionally high in patients with inflammatory bowel disease (IBD). Experimentally, the chronic activation of CD27 as a result of the constitutive expression of CD70 leads to the demise of B cells in bone marrow (BM) and the secondary lymphoid organs. The aim of this study was to assess the number and phenotype of circulating B cell in untreated IBD patients and their counterparts treated with biological anti-TNF drugs. Methods The study involved 13 untreated IBD patients, 36 IBD patients treated with biological drugs, and…

Male0301 basic medicineT-LymphocytesImmunophenotypingB cell homeostasisBiological drugs; Inflammatory bowel diseases; Plasmablasts; TNF-αHomeostasisImmunology and AllergyCD20B-LymphocytesbiologyB-LymphocyteAntibodies MonoclonalMiddle AgedFlow Cytometrymedicine.anatomical_structureFemaleTumor necrosis factor alphaImmunotherapyAntibodyPlasmablastsHumanAdultAdolescentBiological drugImmunologyB-Lymphocyte SubsetsPlasmablastCD19ImmunophenotypingYoung Adult03 medical and health sciencesHomeostasimedicineHumansBiological drugsB cellB-Lymphocyte SubsetPharmacologyTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseInflammatory Bowel Diseases030104 developmental biologyT-LymphocyteTNF-αImmunologybiology.proteinBone marrowbusinessCD27 LigandInternational Immunopharmacology
researchProduct

Tumor Lipids of Pediatric Papillary Renal Cell Carcinoma Stimulate Unconventional T Cells

2020

Papillary renal cell carcinoma (PRCC) is a rare entity in children with no established therapy protocols for advanced diseases. Immunotherapy is emerging as an important therapeutic tool for childhood cancer. Tumor cells can be recognized and killed by conventional and unconventional T cells. Unconventional T cells are able to recognize lipid antigens presented via CD1 molecules independently from major histocompatibility complex, which offers new alternatives for cancer immunotherapies. The nature of those lipids is largely unknown and α-galactosylceramide is currently used as a synthetic model antigen. In this work, we analyzed infiltrating lymphocytes of two pediatric PRCCs using flow cy…

Male0301 basic medicineT-Lymphocytesmedicine.medical_treatmentLymphocyte Activationlipid antigens0302 clinical medicineTumor MicroenvironmentImmunology and AllergyMedicinepediatric papillary renal cell carcinomaChildCells CulturedOriginal Researchmedicine.diagnostic_testbiologyKidney NeoplasmsPhenotypeChild PreschoolCD1DImmunohistochemistrylipids (amino acids peptides and proteins)Signal Transductionlcsh:Immunologic diseases. AllergyAdolescentImmunologyCD1Major histocompatibility complexCD1dPeripheral blood mononuclear cellFlow cytometry03 medical and health sciencesLymphocytes Tumor-InfiltratingAntigenParacrine CommunicationHumansTILsCarcinoma Renal CellCell Proliferationbusiness.industryInfantImmunotherapyLipid Metabolism030104 developmental biologyCase-Control StudiesCancer researchbiology.proteinAntigens CD1dbusinesslcsh:RC581-607unconventional T cells030215 immunologyFrontiers in Immunology
researchProduct

Association between the polymorphisms of TLR4 and CD14 genes and Alzheimer's disease.

2008

Alzheimer's disease (AD) is a heterogeneous and progressive neurodegenerative disease which in Western society mainly accounts for clinical dementia. Inflammation plays a key role in AD and dissecting the genetics of inflammation may provide an answer to the possible treatment. Hence, the better understanding of different molecular and cellular inflammatory mechanisms is crucial for complete knowledge of AD pathophysiology, and for its prevention and drug therapy. Accordingly, in the present study we evaluated whether the pro-inflammatory polymorphisms of lipopolysaccaride-receptors, +896A/G Toll-Like Receptor (TLR4) and -260C/T CD14, are risk factors for AD. The study included both 626 AD …

MaleALZHEIMER'S DISEASEINFLAMMATIONINNATE IMMUNITYTLR4CD14Lipopolysaccharide ReceptorsInflammationSingle-nucleotide polymorphismDiseaseSystemic inflammationPolymorphism Single NucleotideSeverity of Illness IndexDegenerative diseaseINFLAMMATIONAlzheimer DiseaseRisk FactorsDrug DiscoverymedicineDementiaSNPHumansTLR4AgedPharmacologyAged 80 and overbusiness.industryMiddle Agedmedicine.diseaseToll-Like Receptor 4ItalyALZHEIMER'S DISEASEImmunologyINNATE IMMUNITYFemalemedicine.symptomAlzheimer's diseasebusinessCD14
researchProduct

Exploring the MHC-peptide matrix of central tolerance in the human thymus

2013

Ever since it was discovered that central tolerance to self is imposed on developing T cells in the thymus through their interaction with self-peptide major histocompatibility complexes on thymic antigen-presenting cells, immunologists have speculated about the nature of these peptides, particularly in humans. Here, to shed light on the so-far unknown human thymic peptide repertoire, we analyse peptides eluted from isolated thymic dendritic cells, dendritic cell-depleted antigen-presenting cells and whole thymus. Bioinformatic analysis of the 842 identified natural major histocompatibility complex I and II ligands reveals significant cross-talk between major histocompatibility complex-class…

MaleAdolescentT-LymphocytesEnolaseAntigen-Presenting CellsGeneral Physics and AstronomyAutoimmunity610 Medicine & healthPeptideVimentinThymus GlandMatrix (biology)LigandsMajor histocompatibility complexAutoantigensGeneral Biochemistry Genetics and Molecular BiologyMajor Histocompatibility ComplexEpitopesIn vivoHumansMyeloid Cells610 Medicine & healthchemistry.chemical_classificationAntigen PresentationMultidisciplinarybiologyRepertoireHistocompatibility Antigens Class IHistocompatibility Antigens Class IIInfantDendritic CellsGeneral ChemistryCD11c AntigenCell biologychemistryChild PreschoolCentral ToleranceImmunologybiology.proteinFemaleCentral tolerancePeptidesNature Communications
researchProduct